GILD
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FGILD.O%2Fkey-developments%2Farticle%2F2564199&ei=n4aaUoHNENOs0AHkzAE&usg=AFQjCNGg8n2UB5w3cQJEHB08JfGj47EwTQ
Gilead Sciences, Inc. Submits New Drug Application To U.S. FDA For HIV Integrase Inhibitor Elvitegravir For Treatment Experienced Patients
Wednesday, 27 Jun 2012 04:30pm EDT
Gilead Sciences, Inc. announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of elvitegravir, an integrase inhibitor for the treatment of HIV-1 infection in treatment-experienced adults. Elvitegravir is also a component of Gilead’s once-daily Quad single tablet regimen, which is under U.S. and European regulatory review for treatment-naïve adult patients. 
